George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,988.00
Bid: 12,016.00
Ask: 12,020.00
Change: -38.00 (-0.32%)
Spread: 4.00 (0.033%)
Open: 12,070.00
High: 12,144.00
Low: 11,882.00
Prev. Close: 12,026.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CORRECTED-After 4.2 million COVID-19 cases in November, U.S. pins hope on vaccine

Tue, 01st Dec 2020 12:54

(Corrects details of vaccine approval procedure, third
paragraph)

WASHINGTON, Dec 1 (Reuters) - The United States entered the
final month of the year hoping that promising vaccine candidates
will soon be approved to halt the rapidly spreading novel
coronavirus after 4.2 million new cases were reported in
November.

The new COVID-19 cases were more than double the previous
monthly record set in October, as large numbers of Americans
still refuse to refuse to wear masks and continue to gather in
holiday crowds, against the recommendation of experts.

With outgoing President Donald Trump's coronavirus strategy
relying heavily on a vaccine, a Food and Drug Administration
panel of outside advisers will meet on Dec. 10 to discuss
whether to recommend the FDA authorize emergency use of a
vaccine developed by Pfizer Inc.

A second candidate from Moderna Inc could follow a
week later, officials have said, raising hopes that Americans
could start receiving inoculations before the end the year,
although widespread vaccinations could take months.

Other global pharmaceuticals including AstraZeneca PLC
and Johnson & Johnson also have vaccines in the
works, leading a member of the Trump administration's "Operation
Warp Speed" program to predict the country could be vaccinated
by June.

"One hundred percent of the Americans that want the vaccine
will have the vaccine by (June). We will have over 300 million
doses available to the American public well before then," Paul
Ostrowski, the vaccine program's director of supply, production
and distribution, told MSNBC television on Monday.

In the meantime, leading health officials are pleading with
Americans to follow their recommendations and help arrest a
pandemic that killed more than 36,000 people in November,
pushing hospitalizations to a record high of nearly 93,000 on
Sunday, according to a Reuters tally.

The widespread impact of the pandemic has led
Merriam-Webster to choose "pandemic" as the Word of the Year
after it racked up the most online dictionary lookups of any
word.

"Sometimes a single word defines an era, and it's fitting
that in this exceptional - and exceptionally difficult - year, a
single word came immediately to the fore," the dictionary
publisher said.

With more than 10,000 people dying and 1.1 million
contracting the novel coronavirus in the week ended Sunday,
Trump has remained focused on overturning the results of the
Nov. 3 election won by President-elect Joe Biden, denying Trump
a second term.

Biden has pledged to make combating the coronavirus his top
priority upon taking office on Jan. 20, saying he will rely on
the best scientific evidence.

In the absence of a federal blueprint to curb the spread of
the virus, states are issuing new or revamped restrictions on
businesses and social life.

California's governor said he may renew a stay-at-home order
in the coming days, warning that ICU admissions are on track to
exceed statewide capacity by mid-December unless public health
policies and social behavior change.

"The red flags are flying," Governor Gavin Newsom told
reporters in an online briefing. "If these trends continue,
we're going to have to take much more dramatic, arguably
drastic, action."

(Reporting by Reuters staff; Writing by Daniel Trotta; Editing
by Bernadette Baum)

More News
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.